A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes
© Dillon et al.; licensee BioMed Central Ltd. 2014
Received: 30 December 2013
Accepted: 4 June 2014
Published: 15 July 2014
Cancers produce soluble and cell-associated molecules that can suppress or alter antitumor immunity. Preclinical studies suggest the disease burden may alter the cytokine profile of helper T cell responses to cancer antigens. We studied cytokine production by helper T cells responding to vaccination with 6 melanoma helper peptides (6MHP) in blood and lymph nodes.
Twenty-three patients with stage IIIB-IV melanoma received a 6MHP vaccine. Antigen-reactive T cells from blood and draining lymph nodes were cultured, exposed to antigen, and then supernatants (days 2 and 5) were assayed for Th1 and Th2 cytokines. Results from 4 time points were compared to pre-vaccine levels.
Cytokine responses to vaccinating peptides were observed in 83% of patients. Th1 favoring responses were most common (17 of 19 responders). The most abundant cytokines produced were IFN-γ and IL-5 in the PBMC’s. IL-2 responses predominated in cells obtained from draining lymph nodes in 2-day culture but not in 5-day cultures. Patients with clinically measurable disease produced similar levels of total cytokine and similar degree of Th1 polarization as patients with no evidence of disease (NED).
The MHC class II-associated peptides used in this study induced helper T cells with a Th1-biased cytokine response in both PBMC and sentinel immunized nodes. Most patients can mount a Th1 dominant response to these peptides. Future studies are needed to test newer vaccine adjuvants in combination with these peptides.
CDR0000378171, Clinicaltrials: NCT00089219.
Most antigens selected for peptide-based cancer vaccines have been MHC class I restricted; they elicit predominantly CD8+ cytotoxic T-cell responses. The roles for MHC class II associated helper peptides and the CD4+ T-cells which they stimulate have often been viewed as secondary mechanisms in immunotherapy. Nevertheless, it is known that CD4+ T lymphocytes are important in generating effector T cell responses, in “licensing” dendritic cells, and in maintaining immunologic memory [1–4]. They mediate their effects, in part, by the cytokines they produce. The Th1 favoring cytokines (e.g.: IFN-γ, TNF-α, and IL-2) classically support cytotoxic T lymphocyte (CTL) responses, while the Th2 cytokines (e.g.: IL-4, IL-5, IL-10) support generation of antibody responses and may be antagonistic to induction of CTL responses.
We previously employed a tetanus helper peptide AQYIKANSKFIGITEL to stimulate helper T cells. The tetanus helper peptide has been immunogenic and induced Th1-predominant responses . More recently, we have evaluated a multi-epitope vaccine incorporating 6 melanoma helper peptides (6MHP), restricted by HLA-DR molecules, that function as epitopes for CD4+ T cells. This 6MHP vaccine used in the current study is proven to be safe and shows some evidence of clinical activity as previously published . Clinically, objective response was observed in 2 of 17 patients (12%) with measurable disease . The vaccine induced antigen-specific CD4+ T cell responses in over 80% of patients. We previously showed that all 6 helper peptides used for this study are immunogenic and that MAGE-A3281-295 and tyrosinase386-406 have the most frequent responses [6, 7]. Since, the cytokine profile of responding T cells is not previously reported we now report on cytokine profiles of helper peptide vaccinated patients.
Prior in vitro work with human peripheral blood mononuclear cells (PBMC) suggested that disease status (advanced measurable disease vs. clinically free of disease) may direct the Th1/Th2 dominance of T cell responses to helper peptides. In patients bearing measurable advanced renal cell cancer, T cell responses were generated in vitro with dendritic cells (DC) pulsed with helper peptides from MAGE-A6, and responses were highly Th2 dominant, manifested primarily by high IL-5 secretion . In contrast, lymphocytes from patients rendered clinically free of disease by surgery had Th1-dominant responses to the same helper peptides, manifested by high secretion of IFN-γ . The current report is intended to assess whether T cell responses to vaccination with 6 melanoma helper peptides (6MHP) are predominantly Th1 or Th2 dominant, and to obtain preliminary data on whether Th1/Th2 dominance varies as a function of clinical disease status.
Cytokine profiles from 23 vaccinated stage III and IV melanoma patients were assessed from PBMC’s and draining lymph nodes. The lymph nodes collected at day 22 of the 6-vaccine series were surgically resected from the draining nodal basins most proximal to the vaccine sites (sentinel immunized nodes, SIN). We assessed the Th1 favoring cytokines: IFN-γ, TNF-α and IL-2, and the Th2 favoring cytokines: IL-4, IL-5 and IL-10. There were three dose arms in the study, and there were no differences in toxicity nor response by dose (previously published) . The cytokine profiling is performed on supernatants from cultures of lymphocytes derived from draining nodes and from peripheral blood.
The Th1/Th2 cytokine profiles of T cell responses to helper peptide vaccination
Summary of 2-day response data
PBMC (n = 23)
SIN(n = 22)
Number with increase(p value)
Mean at day 22
15 (p = 0.04)
15 (p = 0.07)
10 (p = ns)
7 (p = ns)
14 (p = ns)
9 (p = ns)
17 (p = 0.036)
14 (p = 0.042)
IFN vs IL-5
0.2 vs 8.7
20.7 vs 121
p = 0.005
p = 0.010
p = 0.091
Total cytokines NED
p = 0.11
Total cytokines Disease
5 Day lymphocyte culture increases overall cytokine production, but decreases IL-2 production
Comparison of 2 day to 5 day cytokine responses
2 Day(n = 23)
5 Day(n = 11)
In terms of survival, we observed that stage III and IV patients who were NED at the time of the vaccination achieved a mean survival of 4.9 years. The mean survival for patients with clinically measurable disease was 2.5 years. The 4 patients who had partial responses or stable disease by RECIST had nothing unique about their cytokine profiles at any of the 4 time points tested. They were all Th1 favoring responders by cytokine profiling. We previously reported that those 4 clinical responders all had proliferative responses to vaccine, delayed-typed hypersensitivity and autoimmune phenomena. Due to the small number of responders, we did not find significant correlations between any of the cytokines and clinical response.
Th1/Th2 bias on a per-cell basis
Cytokine profiles in sentinel immunized nodes are not impacted by prior vaccination with class I associated peptides
Helper peptides for cancer vaccination have previously been shown to be immunologically important both alone and as adjuvants [5, 13]. We previously observed that other helper or class II peptides evoked Th1 dominant cytokine responses from stimulated lymphocytes  and now hypothesize that helper peptides specifically from melanoma antigens would also produce Th1 favoring responses. Further, based on published work , we hypothesized that patients with measurable disease might display more Th2-biased responses.
The cytokine profiles of T cells induced by the helper peptides in this vaccine are most consistent with a Th1 dominant profile in 14 of 19 responders (74%) of responders. Interestingly, 2 patients had a Th2-dominant response (one for the 2-day assay and one for the 5-day). Balanced Th1/Th2 responses occurred in 3 patients. Th-1 responses are believed to be most supportive of phagocytic and cytotoxic type tumor responses; the induction of Th2 dominant responses in two patients may be antagonistic to the induction of protective immunity.
It is not known whether the observed Th2 responses represent induction of new Th2 responses, a selective depletion of Th1-responding cells, or a suboptimal vaccination strategy. Future studies to identify molecular mediators of Th2 responses and to characterize further the pleiotropic effects of these cytokines may be informative. Likewise, future evaluation of Th-17 responses elicited by helper peptides is also needed and may further elucidate the relative contribution of Th-2 cytokines in helper responses. In this study, most patients maintained a Th1 dominant response throughout the course of vaccine therapy (Figure 5). Analysis of delayed type hypersensitivity data  also supports an immune response up to 9 months. Questions remain about the need for booster vaccines; these data do not rule out the possibility that booster vaccines may favorably modify the helper T cell response.
The total cytokine production significantly increased from 2 day to 5 day culture, which is not surprising; however, high IL-2 levels were seen in draining nodes in 2 day cultures which were not seen in 5 day node cultures. This likely represents consumption of IL-2 by T cells, during longer culture and could apply either to expansion of activated T cells or induction of regulatory T cells, both of which express the high affinity IL-2 receptor alpha chain (CD25) . Central memory T cells (TCM) respond to antigen by high IL-2 production , thus, the disparate cytokine profiles in the SIN and PBMC suggest that antigen reactive cells in the node (but not in the PBMC) may be enriched for TCM. The loss of IL-2 dominance as TCM respond to antigen and proliferate is also consistent with that observation.
While nearly all patients maintained their overall cytokine profile over time, in a few cases, the Th2/Th1 ratio increased in culture over time, toward slightly lower Th1 predominance. These anecdotal cases highlight the relevance of following immunologic endpoints over time and also highlight the wide degree of variability seen when dealing with human immune monitoring.
It has been reported that PBMC from patients with advanced measurable malignancy may have Th2-dominant responses to helper peptides, whereas those rendered clinically free of disease may have Th1-dominant responses . Our study differs from that report in part by being in melanoma patients rather than renal cell cancer, but more importantly because the induction of the T cell response was in vivo (tested in vitro) rather than being induced in vitro. Our findings do show non-significant trends toward that prior observation, since the only Th2-dominant responses we observed in either 2 or 5 day assay were in metastatic patients with measurable disease, and all of the 12 NED patients had a Th1-dominant response. Also, the total cytokine produced in NED patients trended higher than among those with measurable disease. However, these were not significant differences and were much less pronounced than the prior data after in vitro sensitization. Overall, Th1-dominant responses were most common among both subsets of patients. Anecdotally, prior chemotherapy exposure was not associated with either of two Th2 responses observed.
The observed cytokine response rate of 83% mirrors the proliferative response rate previously reported (81%), but neither immune assay correlates well with the clinical response rate of 12%. The median overall survival for stage IV patients in this study was 2.5 years which is very favorable, but may be influenced by referral bias. In another study with this 6MHP vaccine, immune responses to these 6MHP were strongly and significantly associated with overall survival . However, helper peptide vaccination remains experimental. Further work is needed to optimize adjuvants and to identify measures of immune response associated with favorable outcome. Since this study was designed, we have found that GM-CSF decreases both CD4+ and CD8+ responses to melanoma vaccines in incomplete Freund’s Adjuvant ; thus, we anticipate that vaccination with melanoma helper peptides without GM-CSF or in different adjuvant systems may be even more effective at inducing high magnitude Th1-dominant immune responses.
The MHC class II-associated peptides used in this study induced helper T cells with a Th1-biased cytokine response in both PBMC and sentinel immunized nodes. IL-2 was the dominant Th1 cytokine produced early from SIN, but not from PBMC, and this is consistent with a central memory response in the SIN, which is not surprising since TCM are expected to reside in lymphoid organs. There were exceptions in that several patients had cytokine responses that were either Th2-dominant or Th1-Th2 balanced. The analysis of cytokine profiles over time also suggests that induced helper T cells respond in a specific and stable manner when re-exposed to vaccinating peptides. Clinical disease status did not bias the cytokine polarization in a significant way, though the overall magnitude of cytokine production trends higher in patients without clinically evident disease. Studies in larger patient populations may find significant differences that were not evident here, and if so, that could support different immunotherapy approaches depending on the clinical disease status. Thus, as vaccine adjuvants are improved, analysis of the effects on cytokine profiles in blood and nodes may help to identify patients who may benefit most from helper peptide vaccines.
Patients with AJCC stage IIIB, IIIC or IV melanoma with or without measurable disease were eligible for this vaccine trial. Candidates were required to express at least one of the 5 HLA-DR alleles by which CD4 T cell recognition for these 6 peptides had been defined: HLA-DR1, DR4, DR11, DR13, DR15. Other inclusion criteria and details of the study have been reported . Patients were studied following informed consent, and with Institutional Review Board (HIC#10464) and FDA approval (BB-IND #10825). Baseline demographics are described in Additional file 1: Table S3.
All patients received a vaccine comprising 6 melanoma peptides reported to be restricted by one or more HLA-DR molecules. The peptides and their reported HLA-DR restrictions are AQNILLSNAPLGPQFP (Tyrosinase56-70, HLA-DR4) , FLLHHAFVDSIFEQWLQRHRP (Tyrosinase386-406, HLA-DR15) , RNGYRALMDKSLHVGTQCALTRR (Melan-A/MART-151-73, HLA-DR4) , TSYVKVLHHMVKISG (MAGE-3281-295, HLA-DR11) , LLKYRAREPVTKAE (MAGE-1,2,3,6121-134, HLA-DR13) , and WNRQLYPEWTEAQRLD (gp10044-59, HLA-DR4 & -DR1) [21, 22]. An alanine residue has been added at the N-terminus of AQNILLSNAPLGPQFP (Tyrosinase56-70), to prevent cyclization of the N terminal glutamine residue in the originally described sequence QNILLSNAPLGPQFP [16, 23]. They were prepared under good manufacturing practice (GMP) conditions as described .
The peptides were administered with 110 mcg GM-CSF (Berlex, Seattle, WA) in a stable emulsion with 1 ml Montanide ISA-51 adjuvant (Seppic, Inc., Paris, France/ Fairfield, NJ) days 1, 8, 15, 29, 36, and 43 (weeks 0, 1, 2, 4, 5, and 6). The first 3 vaccinations were divided between two injection sites (primary and replicate), and the last 3 vaccinations were delivered to the primary injection site only. At each injection site, half was administered subcutaneously and half was administered intradermally. Vaccine was administered at 3 dose levels (200 ug, 400 ug and 800 ug, arms A, B and C) with no differences in AE’s nor responses between the dose levels (previously reported). In addition to peptides used in the vaccine, a tetanus helper peptide AQYIKANSKFIGITEL and the irrelevant peptide from HIV gag protein, SLYNTVATL were used in laboratory analyses [11, 24].
Collection of peripheral blood mononuclear cells (PBMC)
Blood was drawn weeks 0, 1, 3, 5, 7, 12, and 18, and at months 6, 9, 12, 18, and 24. Those drawn on weeks 1, 3, 5, and 7 correspond to one week after vaccines 1, 3, 4, and 6, respectively. Lymphocytes isolated from peripheral blood by Ficoll gradient centrifugation were cryopreserved in 10% DMSO/90% serum. Several vaccinated patients were unable to complete all blood draws or had non-viable lymphocytes at time of cytokine analysis; 23 of 37 patients had a minimum of 3 time points with adequate and viable lymphocytes.
Harvest of the sentinel immunized node (SIN)
On day 22 (week 3), the lymph node draining the replicate immunization site, the sentinel immunized node (SIN), was localized and harvested under local anesthesia as reported [25, 26]. A central slice of the SIN was preserved in formalin, and the remainder was dissociated mechanically into a single cell suspension of lymphocytes, and cryopreserved by the University of Virginia’s Tissue Procurement Facility.
Proliferation and cytokine assays
Responses to the six melanoma helper peptides were assessed in vitro by measuring proliferation after antigen exposure. PBMC were thawed in RPMI 1640 medium with 5% heat inactivated human AB serum (HuAB; Gemini Bio-Products, West Sacramento, CA) and DNAse (Worthington Biochemical Corporation, Lakewood, New Jersey, Cat # LS002139; 100 mg, 2,430 units/mg dry weight) at 100 U/ml and washed twice. Cells were adjusted to 1×106 cells/ml in tissue culture medium consisting of AIM V (Invitrogen Corporation/GIBCO, Carlsbad, CA) with heat inactivated 10% HuAB serum, plus each of the following 11 conditions: 1) media only; 2) bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO; 10 ug/ml); 3) tetanus peptide (10 mcg/ml); 4-9) each of the 6 melanoma helper peptides (10 mcg/ml, individually tested); 10) 6 melanoma helper pool (6MHP; all 6 peptides at 10 mcg/ml per peptide); and 11) PHA (Sigma; at 5 mcg/ml). PBMC from two normal donors (Virginia Blood Services, Charlottesville, VA) were included as controls and were stimulated with each of the following 13 conditions: 1) media only; 2) BSA; 3) Tetanus peptide; 4-9) 6-melanoma peptide pool; 10) PHA; 11) influenza lysate, 12) lysate control (Microbix Biosystems Inc., Toronto, Ontario); or 13) PHA. Cultures were assayed in triplicate in 96-well flat bottom cluster dishes and were incubated 5d at 37°C and 5% CO2.
On day 2 or day 5 of the 5-day proliferation assay cultures described above, 50 μl supernatant was removed from each well of the triplicate cultures, pooled and stored at -80°C until tested for Th1 (IFN-gamma, IL-2, TNF-alpha) and Th2 (IL-4, IL-5, IL-10) cytokines by cytokine bead array (BD Biosciences, Franklin Lakes, NJ).
CFSE labeling and in vitro stimulation
Cryopreserved PBMC were thawed in pre-warmed medium (RPMI 1640 + 5% fetal calf serum) containing DNase (Worthington Biochemical Corp., Lakewood, NJ) at 100 units/ml. Viability was determined by Trypan blue dye exclusion, and viable cells were adjusted to 2-4 million/ml in 0.2% BSA in PBS. Cells were labeled using the Vybrant CFDA SE Cell Tracer kit (Invitrogen Corporation/Molecular Probes). Carboxy-fluorescein diacetate, succinimidyl ester (CFDA SE; referred to hereafter as CFSE) was dissolved in DMSO to 10 mM. and diluted to 1 μM in PBS. Equal volumes of cells and dye were combined, incubated 10 minutes at 37°C then washed in AIM V (Gibco/Invitrogen) supplemented with heat inactivated 5% HuAB serum. After stimulation 5d at 37°C with peptide (10 ug/ml) or CD3/CD28 beads (Miltenyi Biotec, Inc., Auburn, CA), cells were collected and prepared for flow cytometric analysis.
Immunological reagents for flow cytometry
Fluorescent tagged antibodies used were specific for: CD3 allophycocyanin (APC), CD3 APC-cyanine7 (Cy7), CD4 phycoerythrin (PE), IL5 PE (BD Biosciences, San Jose CA); CD8 PE-Cy7 (Beckman Coulter Miami FL); IFN-gamma APC, FoxP3 (clone PCH101) and its isotype control (eBiosciences, San Diego CA); CD25-PE (Miltenyi Biotec Inc, Auburn CA).
Intracellular detection of IFNγ and IL-5
Intracellular cytokine (ICC) production by proliferating cells was determined on peptide-stimulated CFSE-labeled PBMC after phorbol 12-myristate 13-acetate (PMA; 40 ng/ml; Sigma-Aldrich) plus ionomycin (1 μM; Sigma). Brefeldin A (10 μg/ml; Sigma-Aldrich) was added to cultures after one hour. After stimulation of PBMC with the pool of 6MHP for 5 days, PMA and Ionomycin in the presence of Brefeldin A was added for 5 additional hours detect cytokines produced by dividing cells. For flow cytometric analysis, the CD3posCD8neg T cell population served as a surrogate CD4 population because PMA is known to down-modulate surface CD4. Cells were harvested 5h later and surface-stained with anti–CD3 APC-Cy7 and –CD8-PE-Cy7, then washed, fixed and permeabilized (Cytofix/CytoPerm™, BD Biosciences) before staining with anti-IL5 PE and anti-IFN-gamma APC. Cells were collected on a modified Becton Dickinson FACSCalibur dual laser (488 nm and 637 nm) benchtop cytometer (FACSCalibur A) capable of 7 parameter (five color) analysis. Data were analyzed with FloJo (Treestar, Ashland OR) software. Gates and parameter thresholds were set using unstained cells as controls.
Positive and negative controls were performed and all results adjusted accordingly. Non-specific and background cytokine production was accounted for by use of controls and baseline subtraction. Cytokine levels were rescaled using the square root transformation for some figures, and in the case of PBMC’s, readjusted by subtraction of the baseline cytokine level. Summary statistics were calculated for levels of cytokine. Paired and two sample t-tests were used to compare cytokine levels across various factors. Levels of cytokine were assessed across treatment arms using linear regression methods. Survival function was performed in SAS. The overall study was not powered for assessing multiple cytokine profiles, however cytokine profiling by study arm and disease status were pre-planned analyses in the study protocol.
We thank Patrice Neese and Carmel Nail for administering vaccines and for recording and managing toxicities; Donna Deacon for vaccine preparation. We also thank clinical research coordinators Jennifer Hodges and Emily Jackson. The regulatory and auditing work was supported and overseen by a team including Robyn Fink, Elizabeth Woodson, Sarah Lewis, Christine Schulte, Scott Boerner, Erin Farris, Beverely Turner, and Kim Underwood.
This study was funded by NIH/NCI grant R21 CA105777 (to C.L.S) and U01 CA178846 (to C.L.S.). Support was also provided by the University of Virginia Cancer Center Support Grant (NIH/NCI P30 CA44579, Clinical Trials Office, Tissue Procurement Facility, Flow Cytometry Core, and Biomolecular Core Facility); the UVA General Clinical Research Center (NIH M01 RR00847). Peptides used in this vaccine were prepared with philanthropic support from the Commonwealth Foundation for Cancer Research and Alice and Bill Goodwin. GM-CSF (made by Berlex originally/now Genzyme) and Montanide ISA-51 (made by Seppic, Inc.) were used in the vaccines in this trial, but these were paid for by the University of Virginia. No corporate funding support was provided for this study. Berlex/Genzyme has provided support (in the form of GM-CSF at no charge) for a different clinical trial, for which Dr. Slingluff was the study chair; so he has a relationship with Berlex related to that separate support.
- Mortara L, Gras-Masse H, Rommens C, Venet A, Guillet JG, Bourgault-Villada I: Type 1 CD4 (+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J Virol. 1999, 73: 4447-4451.PubMedPubMed CentralGoogle Scholar
- Schoenberger SP, Toes RE, van der Voort EL, Offringa R, Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998, 393: 480-483.View ArticlePubMedGoogle Scholar
- Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD4+ T-cells in the antitumor immune response. JEM. 1998, 188: 2357-2368.View ArticleGoogle Scholar
- Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Carbone DP, Liotta LA, Berzofsky JA: A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. JI. 1999, 163: 184-193.Google Scholar
- Slingluff CL, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, Parekh J, Neese PY, Woodson EM, Wiernasz CJ, Merrill P:Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004, 22: 4474-4485.View ArticlePubMedGoogle Scholar
- Slingluff CL, Petroni GR, Olson W, Czarkowski AR, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK: Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008, 26: 4973-4980.View ArticlePubMedPubMed CentralGoogle Scholar
- Hu Y, Petroni GR, Olson WC, Czarkowski A, Smolkin ME, Grosh WW, Chianese-Bullock KA, Slingluff CL: Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother. 2014, [Epub ahead of print]Google Scholar
- Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4 (+) T cell responses against MAGE-6 in HLA-DRB10401 (+) patients with renal cell carcinoma or melanoma. JEM. 2002, 196: 619-628.View ArticleGoogle Scholar
- Rackowski JL, Haggarty BS, Gaulton GN, Hoxie: T4 endocytosis and phosphorylation induced by phorbol esters but not by mitogen or HIV infection. J Immunolo. 1988, 140: 786-795.Google Scholar
- Slingluff CL, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK: Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res. 2007, 13: 6386-6395.View ArticlePubMedGoogle Scholar
- Deacon DH, Hogan KT, Swanson EM, Chianese-Bullock KA, Denlinger CE, Czarkowski AR, Schrecengost RS, Patterson JW, Teague MW, Slingluff CL: The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines. BMC Cancer. 2008, 8: 360-View ArticlePubMedPubMed CentralGoogle Scholar
- Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG: Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001, 7: 3012-3024.PubMedGoogle Scholar
- Slingluff CL, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood J: A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res. 2013, 19 (15): 4228-4238.View ArticlePubMedGoogle Scholar
- Claret E, Renversez JC, Zheng X, Bonnefoix T, Sotto JJ: Valid estimation of IL2 secretion by PHA-stimulated T-cell clones absolutely requires the use of anti-CD25 monoclonal antibody to prevent IL2 consumption. Immunol Lett. 1992, 33 (2): 179-85.View ArticlePubMedGoogle Scholar
- Kallies A: Distinct regulation of effector and memory T-cell differentiation. Immunol Cell Biol. 2008, 86: 325-32.View ArticlePubMedGoogle Scholar
- Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF: Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. JEM. 1996, 183: 1965-1971.View ArticleGoogle Scholar
- Kobayashi H, Kokubo T, Sato K, Kimura S, Asano K, Takahashi H, Iizuka H, Miyokawa N, Katagiri M: CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res. 1998, 58: 296-301.PubMedGoogle Scholar
- Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL, Sidney J, Sette A, Storkus WJ: Melan-A/MART-1 (51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4 (+) T cells. Proc Natl Acad Sci U S A. 2000, 97: 400-405.View ArticlePubMedPubMed CentralGoogle Scholar
- Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP: Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. JEM. 1999, 189: 871-876.View ArticleGoogle Scholar
- Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P: Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4 (+) T lymphocytes. JEM. 1999, 189: 767-778.View ArticleGoogle Scholar
- Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacker H: Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. 1997, 57: 3238-3244.PubMedGoogle Scholar
- Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Muller C, Zeuthen J, Pawelec G: Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother. 1998, 47: 32-38.View ArticlePubMedGoogle Scholar
- Thompson LW, Hogan KT, Caldwell JA, Pierce RA, Hendrickson RC, Deacon DH, Settlage RE, Brinckerhoff LH, Engelhard VH, Shabanowitz J, Hunt DF, Slingluff CL: Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity. J Immunother. 2004, 27: 177-183.View ArticlePubMedGoogle Scholar
- Johnson RP, Trocha A, Yang L, Mazzara GP, Panicali DL, Buchanan TM, Walker BD: HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes: Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. JI. 1991, 147: 1512-1521.Google Scholar
- Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Teates D, Neese P, Grosh WW, Petroni G, Engelhard VH, Slingluff CL: Evaluation of peptide vaccine immunogenicity in draining lymph nodes and blood of melanoma patients. Int J Cancer. 2001, 92: 703-711.View ArticlePubMedGoogle Scholar
- Slingluff CL, Yamshchikov GV, Hogan KT, Hibbitts SC, Petroni GR, Bissonette EA, Patterson JW, Neese PY, Grosh WW, Chianese-Bullock KA, Czarkowski A, Rehm PK, Parekh J: Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Ann Surg Oncol. 2008, 15: 3538-3549.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.